# Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

> **NCT01786265** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 310 (estimated)

## Conditions studied

- Prostate Adenocarcinoma
- Recurrent Prostate Carcinoma

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Bicalutamide
- **DRUG:** Degarelix
- **DRUG:** Flutamide
- **DRUG:** Goserelin Acetate
- **DRUG:** Leuprolide Acetate
- **DRUG:** Nilutamide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01786265
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-02-05
- **Primary completion:** 2027-02-01
- **Final completion:** 2027-02-01
- **Target enrollment:** 310 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01786265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01786265, "Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT01786265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*